According to AMR’s prediction, Hormone-refractory prostate cancer, also known as castration-resistant prostate cancer (CRPC), is a type of prostate cancer that no longer responds to hormonal therapies used to reduce levels of androgens, such as testosterone. Prostate cancer cells require androgens to grow and divide, and hormone therapy is often used as a first-line treatment to …